← Back to Search

Other

Deprescribing Intervention for Overmedication

N/A
Waitlist Available
Led By Lisa Herrinton, PhD
Research Sponsored by Kaiser Permanente
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up difference between (days 181-365 after randomization) and (180 days before randomization)
Awards & highlights
No Placebo-Only Group

Summary

This trial tested a quality intervention intended to reduce hyperpolypharmacy in older patients, potentially reducing adverse effects. Results showed changes in medications and geriatric syndrome, and monitored utilization and withdrawal effects.

Who is the study for?
This trial is for Kaiser Permanente patients aged 76 or older who are taking 10 or more prescription medications. Candidates must have filled their prescriptions at least twice in the past year and most recently within the last six months. Those with less than a year's enrollment, no primary care practitioner, on dialysis, in hospice, recent cancer treatment, or organ transplant history are excluded.
What is being tested?
The study tests a deprescribing intervention to reduce medication use among elderly patients overmedicated with prescription drugs. It involves collaboration between doctors and pharmacists to manage drug therapy by phone over several cycles up to 180 days. The main goal is to see if this can decrease medication numbers and geriatric syndrome prevalence.
What are the potential side effects?
Potential side effects may include adverse reactions from reducing medications such as withdrawal symptoms or changes in health status due to alterations in drug therapy. These will be monitored through patient utilization patterns and recorded health data.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~difference between (days 181-365 after randomization) and (180 days before randomization)
This trial's timeline: 3 weeks for screening, Varies for treatment, and difference between (days 181-365 after randomization) and (180 days before randomization) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Pharmaceutical Preparations
Syndrome
Secondary study objectives
Utilization
Other study objectives
Adverse drug withdrawal effects

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Bundled hyperpolypharmacy interventionExperimental Treatment1 Intervention
Eligible participants with physician authorization who are randomly assigned to intervention
Group II: ControlActive Control1 Intervention
Eligible participants with physician authorization who are randomly assigned to usual care

Find a Location

Who is running the clinical trial?

Kaiser PermanenteLead Sponsor
556 Previous Clinical Trials
27,729,764 Total Patients Enrolled
Lisa Herrinton, PhDPrincipal InvestigatorKaiser Permanente

Media Library

Bundled Hyperpolypharmacy Deprescribing (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05616689 — N/A
Overmedication Research Study Groups: Bundled hyperpolypharmacy intervention, Control
Overmedication Clinical Trial 2023: Bundled Hyperpolypharmacy Deprescribing Highlights & Side Effects. Trial Name: NCT05616689 — N/A
Bundled Hyperpolypharmacy Deprescribing (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05616689 — N/A
~478 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top